CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,874 enrolled
Drug / intervention
Timing of return of resultsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06748040
NCT06748040N/ACompleted
CompareCT.gov

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States - Pharmacogenetic Substudy

Duke University·interventional·Posted Dec 24, 2024·Updated Jun 17, 2025

In Brief

A clinical study evaluating Timing of return of results for Chronic Kidney Disease and Hypertension. Completed, enrolled 1,874 participants across 8 sites.

Detailed Summary

This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824). Its primary purpose is to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in SBP (systolic blood pressure) from baseline to 3 months in APOL1 (apolipoprotein L1) negative individuals at participating sites.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, Hypertension
CountriesUnited States
CollaboratorsNational Human Genome Research Institute (NHGRI), Icahn School of Medicine at Mount Sinai, University of Florida, Indiana University

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 24, 2024
Enrollment StartJul 10, 2020
Primary CompletionApr 9, 2024
Study CompletionMay 17, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 1.5 years ago

Interventions

Timing of return of resultsother

Participants will be randomized to immediate versus delayed return of PGx results.